Zogenix rises on FDA acceptance of Zohydro ER NDA
This article was originally published in Scrip
Executive Summary
Shares of Zogenix jumped 17.6% on 16 July on word the US FDA accepted for review the firm's new drug application (NDA) for its oral extended-release hydrocodone therapy Zohydro as a treatment for moderate to severe chronic pain.